20046 ⎘
Medicinal preparations characterised by special physical form; Galenical forms characterised by the site of application; Pulmonary tract; Aromatherapy Lung surfactant, artificial mucus
Surfactant Formulations for Inhalation
#2SILK FIBROIN-CONTAINING COMPOSITION AND METHODS OF USE THEREOF
#3PROCESS FOR THE PREPARATION OF A PULMONARY SURFACTANT
#4POLYMER LUNG SURFACTANTS
#5MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES AND USES THEREOF FOR TREATING AND DIAGNOSING FIBROTIC DISEASES
#6MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES AND USES THEREOF FOR TREATING AND DIAGNOSING FIBROTIC DISEASES
#7SOLUTION AND METHOD FOR REDUCING THE VIRULENCE OF VIRUSES, BACTERIA, YEASTS, OR FUNGUS
#8Surfactant Formulations for Inhalation
#9Solution and method for reducing the virulence of viruses, bacteria,yeasts, or fungus
#10NEURONAL AGONISTS AND ISOTONIC OR HYPERTONIC SALINE FOR TREATING RESPIRATORY DISEASES
#11Polymer lung surfactants
#12ANTIFIBROTIC COMPOSITION
#13LUNG SURFACTANT-BASED ANTICANCER DRUG
#14SILK FIBROIN-CONTAINING COMPOSITION AND METHODS OF USE THEREOF
#15Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases
#16DILUTE SURFACTANT OR ISOLATED SURFACTANT PROTEIN SOLUTION FOR THE REDUCTION OF SURFACE TENSION IN THE LUNG
#17POLYMER LUNG SURFACTANTS
#18METHODS AND COMPOSITIONS FOR TREATING LUNG DISEASE OF PREMATURITY
#19METHODS AND COMPOSITIONS FOR DELIVERY OF MEDICAMENTS TO THE LUNGS
#20Nylon-3 co-polymers and synthetic lung surfactant compositions containing same
#21Polymer lung surfactants
#22Use of Simple Amino Acids to Form Porous Particles
#23Dilute surfactant or isolated surfactant protein solution for the reduction of surface tension in the lung
#24Use of Simple Amino Acids to Form Porous Particles
#25Dithiol mucolytic agents
#26Use of rhodamine dyes to reduce alveolar surface tension
#27Lyophilization of synthetic liposomal pulmonary surfactant
#28Nylon-3 co-polymers and synthetic lung surfactant compositions containing same
#29Dithiol mucolytic agents
#30METHODS AND COMPOSITIONS FOR DELIVERY OF MEDICAMENTS TO THE LUNGS
#31Phospholipid-based powders for drug delivery
#32Synthetic lung surfactant and use thereof
#33Humidified particles comprising a therapeutically active substance
#34Nylon-3 co-polymers and synthetic lung surfactant compositions containing same
#35Surfactant composition
#36Phospholipid-based inhalation system
#37Use of simple amino acids to form porous particles
#38Method of administration of a pulmonary surfactant
#39Artifical Pulmonary Surfactant Compositions
#40Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
#41Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C)
#42REDUCING THE RISK OF CHRONIC LUNG DISEASE IN INFANTS
#43Methods and Compositions for Delivery of Medicaments to the Lungs
#44Synthetic lung surfactant and use thereof
#45Phospholipid-based powders for drug delivery
#46Method of administration of a pulmonary surfactant
#47Artificial pulmonary surfactant compositions and use of the same
#48USE OF SIMPLE AMINO ACIDS TO FORM POROUS PARTICLES
#49USE OF SIMPLE AMINO ACIDS TO FORM POROUS PARTICLES
#50Phospholipid-based inhalation system
#51Lung Surfactant Supplements
#52Composition comprising a pulmonary surfactant and a TNF-derived peptide
#53Reducing the risk of chronic lung disease in infants
#54Treatment and prevention of asthma
#55Use of simple amino acids to form porous particles
#56Pulmonary surfactant formulations
#57Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
#58Methods, systems and devices for delivery of pulmonary surfactants